Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Gains from Investment Securities (2016 - 2023)

Historic Gains from Investment Securities for Spyre Therapeutics (SYRE) over the last 9 years, with Q2 2023 value amounting to $63.4 million.

  • Spyre Therapeutics' Gains from Investment Securities rose 1468261.42% to $63.4 million in Q2 2023 from the same period last year, while for Mar 2024 it was $8000.0, marking a year-over-year increase of 10134.91%. This contributed to the annual value of -$915000.0 for FY2023, which is 10903.52% down from last year.
  • Spyre Therapeutics' Gains from Investment Securities amounted to $63.4 million in Q2 2023, which was up 1468261.42% from $8000.0 recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' Gains from Investment Securities registered a high of $63.4 million during Q2 2023, and its lowest value of -$836000.0 during Q4 2022.
  • In the last 5 years, Spyre Therapeutics' Gains from Investment Securities had a median value of $8000.0 in 2020 and averaged $3.8 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 59467.46% in 2022, then skyrocketed by 1468261.42% in 2023.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Gains from Investment Securities stood at $7000.0 in 2019, then dropped by 28.57% to $5000.0 in 2020, then skyrocketed by 3280.0% to $169000.0 in 2021, then plummeted by 594.67% to -$836000.0 in 2022, then surged by 7685.82% to $63.4 million in 2023.
  • Its last three reported values are $63.4 million in Q2 2023, $8000.0 for Q1 2023, and -$836000.0 during Q4 2022.